Dan Stanton, Managing editor

June 7, 2019

3 Min Read
Pluristem looks to cell cultured cannabinoids
Image: iStock/RaStudio

Pluristem Therapeutics has filed a provisional patent application to use its 3D cell culturing technology to manufacture cannabinoid-producing cells.

Pluristem has several candidates in its pipeline based on placenta-derived, mesenchymal-like adherent stromal cells, has inked a recent study agreement with NASA, and is working with Thermo Fisher to address the lack of technologies available to cell therapy manufacturers for the cultivation and processing of allogeneic products.

Now the Israeli cell therapy firm is looking to use its cell culture platform to address the burgeoning cannabinoid space, filing a patent application entitled ‘Methods and Compositions for Producing Cannabinoids.’


Image: iStock/RaStudio

The patent covers the use of Pluristem’s platform for the growing of cannabinoid-producing cells, offering an alternative to the resource-intensive cultivating of cannabis plants in the production of therapeutic cannabinoid-based products.

Isolation and growth

“Our cell culture system is composed of three-dimensional macro carriers inside a tightly controlled bioreactor system,” Pluristem spokesperson Efrat Kaduri told Bioprocess Insider.

“In the case of cannabinoids, we can potentially isolate and grow the cells that produce the cannabinoids in the cannabis plant. Because our system allows three-dimensional structures to grow on a solid substrate protected from shear forces and because it is highly controlled, it can allow the cannabis-producing cells to grow without the support of the plant.”

The system provides the nutrients and environmental conditions required for the growth and production of secondary metabolites. In this case it relates to cannabinoids, but Kaduri said it can theoretically be applied to other plant-based products.

“Because plants – and the cells that build them – are complex three-dimensional creatures, our culturing system can provide the needed environmental conditions as the plant itself, and thus by adjusting the components of the medium and environmental conditions (temperature, pH, oxygen) it can theoretically grow cells from different plants responsible for the production of secondary metabolites – antibiotics, nicotine, cannabinoid, etc.”


According to Kaduri, making cannabinoids using cell culture systems can reduce production costs.

“First of all, the raw materials for the production of plant cells are much cheaper than those of stem cells,” he said. “Second, in one bioreactor, cannabinoid producing cells can potentially be grown in quantities equal to many plants but on a very small surface area. Therefore, on the same growth area a lot more product can be produced.”

She continued: “In standard farming, the growth area can be used for 3-4 cycles per year. In our system, because we potentially don’t wait for the plant to fully mature and instead we seed the cannabinoid producing cells, a lot more cycles could be done in a year.”

Moreover, there is greater reproducibility and batch security, she added. “In our cannabinoid system it should be possible to receive the same product each time by creating an intermediate plant cell stock. In every cycle we can potentially take the same cells and because the system is a closed system the fear from plant contamination decreases.”

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like